Turning Point Therapeutics EBIT

Turning Point Therapeutics (TPTX) currently reports a EBIT of $-340M as of June 2022. That compares with $-160M in the prior-year period — down 118.2% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Turning Point Therapeutics's EBIT history and peer comparisons.

Turning Point Therapeutics's EBIT decreased from $-160M to $-340M — a 118.2% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Turning Point Therapeutics's EBIT of $-340M is lower than the Healthcare sector average of $110B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Turning Point Therapeutics reported $-340M in EBIT as of June 2022. That compares with $-160M in the prior-year period — down 118.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-340M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Turning Point Therapeutics, and consider following TPTX for alerts when major investors trade the stock.